GI-View

Company Overview

Snapshot

Founded in April 2003, GI-View operates with 11–50 employees, having raised a total of $23 million across two funding rounds. The company achieved a significant milestone in September 2016 by securing FDA 510(k) clearance for its Aer-O-Scope Disposable Colonoscope System, enabling therapeutic intervention during colorectal cancer screening.

Business overview

GI-View is a medical device startup focused on developing disposable endoscopes, specifically single-use colonoscopes. Their core product, the Aer-O-Scope, addresses concerns about disease transmission and hygiene associated with reusable endoscopes. This technology provides a panoramic view for detecting polyps behind colonic folds and features a hydrophilic coating to reduce forces on the colonic wall. GI-View serves the healthcare industry, particularly hospitals and clinics, within the Health Tech & Life Sciences sector, with a focus on diagnostics, gastroenterology, and early detection of colorectal cancer.

Strategic signal

In September 2016, GI-View received FDA 510(k) clearance for its Aer-O-Scope Disposable Colonoscope System, which includes working channels for therapeutic intervention during colorectal cancer screening. This regulatory approval is a strong signal of product validation and market readiness, indicating the company's ability to meet stringent medical device standards and potentially expand its market reach within the diagnostics and gastroenterology sectors.

Company Intelligence Q&A

What is GI-View's primary product?

GI-View's primary product is the Aer-O-Scope, a disposable, single-use colonoscope designed to address hygiene concerns and improve visualization during colorectal cancer screening.

When was GI-View founded?

GI-View was founded in April 2003.

What was a significant regulatory achievement for GI-View?

In September 2016, GI-View received FDA 510(k) clearance for its Aer-O-Scope Disposable Colonoscope System, which includes working channels for therapeutic intervention during colorectal cancer screening.

What is the total capital raised by GI-View?

GI-View has raised a total of $23 million across two funding rounds.

What problem does GI-View's technology aim to solve?

GI-View's technology aims to solve the problem of disease transmission and hygiene concerns associated with reusable endoscopes by offering a disposable colonoscope, while also improving visualization for polyp detection.